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Abstract
Introduction: A duodenal Gastrointestinal Stromal Tumour (GIST) is a rare finding and until
recently advanced disease had a poor prognosis. A PubMed search revealed no reports of more
than five years survival of inoperable GIST on chemotherapy with WHO performance status zero.
Case Presentation: A 68 year old female was diagnosed with unresectable GIST in the
duodenum with metastasis to liver, pancreas and omentum in November 2001. She was
commenced on imatinib mesylate (Glivec) chemotherapy. This case report was prepared from the
medical records and radiology reports. She had good tolerance with stable disease. After six years
her CT scan showed no disease progression and her WHO performance status was zero.
Conclusion: This report supports the view that imatinib is a safe and effective drug in controlling
disease progression in advanced metastatic GIST and plays an important role in improving the
patient's quality of life.
Introduction
A duodenal tumour, especially a gastrointestinal stromal
tumour (GIST), is a rare finding and until recently
advanced disease had a poor prognosis. A PubMed search
revealed only a few reports of prolongation of the lives of
patients with advanced duodenal GIST by treatment with
imatinib. The maximum length of follow up was 29
months [1] from diagnosis. A recent study suggested that
the prognosis for unresectable and/or metastatic GIST is
poor with few if any patients surviving more than five
years [2].
Case Presentation
A previously fit and well, 68-year-old female presented in
November 2001 with recent onset of epigastric discom-
fort, significant loss of appetite and melaena. She had also
lost 5 kilos in weight over a three-week period. Over the
previous few weeks, she was mostly confined to bed, as
she was extremely lethargic.
Upper gastrointestinal endoscopy (Figure 1c) revealed a
pre-ampullary tumour in the second part of the duode-
num. Histology confirmed the tumour to be a GIST with
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(HPF) (Figure 1a). The tumour was found to be positive
for a deletion mutation in exon-11 (of the c-KIT exon)
(Figure 1b). Computerised tomography (CT) of the abdo-
men showed multiple metastatic deposits in the liver (Fig-
ure 2a). At laparotomy the tumour was found to involve
the liver, pancreas and omentum. A hard lump in the right
paracolic gutter was inseparable from the right kidney.
Owing to the extensive nature of the disease the abdomen
was closed without any resection.
Oncology assessment recorded a WHO performance sta-
tus of three (see Additional file 1). She was commenced
on Imatinib Mesylate (Glivec) 400 mg once daily. By Sep-
tember 2002 her WHO performance status was zero. She
had mild nausea but her appetite was normal and she had
no urinary or bowel symptoms. Full blood counts and
renal function tests were normal. Her liver function tests
were abnormal even before treatment, probably a result of
hepatic metastases, and this persisted.
After 28 months of treatment she developed minor side
effects including infrequent diarrhoea and watery painful
eyes. Her regime was modified to four weeks on treatment
with an off period for the next two weeks and this
improved her symptoms. The daily dose remained at 400
mg. At her most recent review in December 2007 she
remained symptomatically well. She was mobile and had
no difficulties in performing her daily activities. She was
followed up with a CT scan (Figure 2b and 2c) but she
refused any further endoscopic investigations.
Discussion
GIST is a rare form of sarcoma arising either from the
interstitial cells of cajal (ICCs) or from less differentiated
stem cells. The ICCs are located in the muscle layer of the
gastrointestinal tract. GIST can occur anywhere but
mainly affects the stomach (60%), jejunum and ileum
(30%), duodenum (4–5%), rectum (4%), colon and
appendix (1–2%) and oesophagus (<1%) [3]. Rarely
extra-gastrointestinal GIST occurs in the vicinity of the
stomach or intestines [3]. The overall incidence has been
estimated at 10–20 per million.
CT scan imagesFigure 2
CT scan images. a: at diagnosis (November 2001) b and c: 
at the last follow up (in December 2007).
Microscopy and Endoscopy pictures at diagnosis in Novem-ber 2001Figure 
Microscopy and Endoscopy pictures at diagnosis in 
November 2001. a: shows pictures of H and E staining, b: 
KIT positive staining c: Endoscopic findings.Page 2 of 4
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whether tumour size, mitotic activity and genetic charac-
teristics predict disease progression. GISTs more than 5
cm in size, independent of mitotic rate, have a moderate
risk for metastases, and all tumours with less than 5
mitoses per 50 HPFs have a high risk for metastases. Miet-
tinen and Lasota reasoned that when data are analysed by
regression models tumour size may appear to show
greater predictive value because mitotic count reaches a
'saturation point' when counts exceed 10 per 50 HPFs [3].
Bearzi et al [4] reviewed 158 cases of GIST. Only 12% of
patients with a mitotic count over 10 per 50 HPFs
remained disease-free after surgery, and all patients with a
mitotic count over 20 per 50 HPFs experienced recurrence.
They argued that if the combination of size and mitotic
count place a tumour in the high-risk category, then the
mitotic count might be the more indicative variable.
Recent papers suggest a mutation found in a GIST may
predict its likelihood of recurrence. Emile et al [5] and
Martin et al [6] identified specific mutations within c-KIT
exon 11 which were associated with metastasis and poor
prognosis. Several papers have found that patients with
deletions in exon-11 rather than substitutions or duplica-
tions have a greater probability of recurrence or metastasis
than other GIST patients [7,8].
If these results are confirmed and expanded they could
provide a rationale for identifying patients who need
closer monitoring or perhaps adjuvant chemotherapy
post-surgery to prevent recurrence rather than after the
appearance of metastasis in line with guidance by the UK
National Institute of Clinical Excellence (NICE; see Addi-
tional file 2).
Cell proliferation in a GIST is a result of the activation of
growth factor receptors. KIT and platelet derived growth
factor receptor alpha (PDGFRA) tyrosine kinases [9] are
normally present on the ICCs. When the genes of these
receptor cells are mutated activation take place without
stimulation by the respective ligands (constitutive activa-
tion). This causes tumour growth.
Imatinib Mesylate (Glivec) is the first effective treatment
for GIST. Imatinib binds to the intracellular activation
pockets of the KIT and PDGFRA receptors in their inactive
position, blocking their binding to ATP and preventing
growth signals being sent, which stops disease progres-
sion. Drug response is related to the type of mutation of
the c-KIT exon. Patients with the more common exon-11
mutation are most sensitive to imatinib [10] whereas
patients with the exon-9-mutation, mostly found in those
with small intestinal GIST, are the least sensitive [11].
The most commonly reported side effects of imatinib are
nausea, diarrhoea, periorbital oedema, muscle cramps,
fatigue, rash and headache. The most common serious
adverse events are unspecified haemorrhage and neutro-
penia, each occurring in approximately 5% of patients
(see Section 4.1.9 in [2]).
In our patient, imatinib was extremely effective in control-
ling the disease process. This was most likely a result of the
type of mutation (exon-11) that was present in this
tumour. The WHO performance status at diagnosis was
three. Since September 2002, her WHO performance sta-
tus has remained at zero. She had suffered from minor
side effects of the drug like diarrhoea and watery painful
eyes. She was reviewed in the oncology clinic and the
change of regime to four weeks on and two weeks off the
drug relieved these side effects.
Conclusion
There have been articles published on the effectiveness of
imatinib but very few have shown a six-year disease-con-
trolled survival with a good quality of life when extensive
spread of the disease was apparent at diagnosis. NICE [2]
guidance (see Additional file 2) suggests imatinib should
only be used in patients with established metastases,
unresectable disease or residual disease following surgery.
The effectiveness of this drug is dependent on the type of
mutation of the c-KIT exon. Knowledge of this mutation
would thus help in assessing the prognosis of treatment.
We believe our report supports the view that imatinib is a
safe and effective drug in controlling disease progression
in advanced metastatic GIST and plays an important role
in improving the patient's quality of life.
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